Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Capital One Financial Corp. (COF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Capital One Financial Corp. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Capital One Financial Corp. trades at $203.1 (market cap $124.14B). The key difference: Capital One Financial Corp. is far larger — about 3.1× Alnylam Pharmaceuticals, Inc.'s market cap, and Capital One Financial Corp. pays a 1.59% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | COF | |
|---|---|---|
Market Cap | $39.89B | $124.14B |
Sector | Health | Financials |
52-Week High | $491.22 | $257.94 |
52-Week Low | $278.09 | $176.10 |
Enterprise Value | $38.15B | — |
Dividend Yield | — | 1.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Capital One (COF) trades at $201.52, up 0.71% with a bearish technical signal but strong analyst support. The company reported mixed Q1 2026 earnings with a slight miss, while revenue surged to $53.43B in 2025. Key risks include subprime auto loan delinquencies and consumer credit stress, though the Discover integration offers long-term scale benefits. Technical indicators show neutral RSI readings with support at $195 and resistance at $203.
Wall Street maintains a bullish outlook with 62.5% buy ratings and a $256.25 consensus price target, representing 27% upside potential. However, declining profit margins and rising default risks in consumer lending create headwinds. The stock presents a compelling entry point for investors betting on operational improvements from recent acquisitions, though credit quality trends warrant close monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Capital One Financial Corp.
Capital One is a diversified financial services holding company headquartered in McLean, Virginia. Originally a spinoff of Signet Financial's credit card division in 1994, the company is now primarily involved in credit card lending, auto loans, and commercial lending.
Read more on COF →
